EntreMed Inc. reported financial results for the first quarter ended March 31, 2013. The company reported a net loss for the first quarter of approximately $1.1 million, or $0.05 per share, compared with a net loss of $2.5 million, or $0.23 per share, for the same period last year. The reported net loss for the three months ended March 31, 2012 included non-cash interest charges totaling approximately $0.9 million associated with the company's 2012 financing, recorded in accordance with US generally accepted accounting principles.

EntreMed Inc. announced that on April 4, 2013, Mark C. M. Randall resigned from the Board of Directors of the company effective immediately. Prior to his resignation, Mr. Randall was a member of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. On April 4, 2013, the Board elected James Huang as a director, effective immediately. Mr. Huang will stand for election at the company’s 2013 annual meeting of stockholders. Mr. Huang is managing partner of Kleiner Perkins Caufield Byers China and general partner of KPCB China Fund II, LP, which invested in the company’s previously announced registered direct financing that closed in March 2013. On April 4, 2013, the Board also elected Alexander as a director, effective immediately. Dr. Wu also will stand for election at the company’s 2013 annual meeting of stockholders.

EntreMed Inc. announced that its board of directors has appointed two new individuals as directors. Joining the Board are James Huang and Y. Alexander Wu, Ph.D. James Huang is Managing Partner of Kleiner Perkins Caufield Byers China and General Partner of KPCB China Fund II, LP, which invested in the company's previously announced registered direct financing that closed in March 2013. Prior to Kleiner Perkins, Mr. Huang was Managing Partner at Vivo Ventures LLC. Mr. Huang has over 20 years of experience in the pharmaceutical and biopharmaceutical industry. During this time, he has held senior roles in business development, sales, marketing and R&D with Anesiva Inc., Tularik Inc., GlaxoSmithKline LLC, Bristol-Meyers Squibb and ALZA Corp. Y. Alexander Wu, Ph.D. is co-founder and CEO of Crown Bioscience Inc. Before co-founding Crown Bioscience, Alex was Chief Business Officer of Starvax International Inc. Prior to Starvax, he was the Head of Asian Operations with Burrill & Company. Dr. Wu also co-founded and was Chief Operating Officer of Unimicro Technologies. He started his career with Hoffmann-La Roche, where he was Manager of Business Development and Strategic Planning. The company further announced that Ken K. Ren, Ph.D. has been appointed Chief Executive Officer, after having completed his one-year term as interim CEO.